15 hours ago
/C O R R E C T I O N -- Human Longevity, Inc./
In the news release, Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members, issued 17-Jun-2025 by Human Longevity, Inc. over PR Newswire, we are advised by the company that the media contact information should be added to the public distribution. The complete, corrected release follows:
SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs.
Driving Innovation in Early Detection
Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking.
These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test.
In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers.
How the $1 Million Pledge Works
Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include:
Whole genome sequencing
Whole-body MRI, with dedicated pancreatic imaging
Long-term blood biomarker analysis
A DNA-based pancreatic cancer screening blood test
Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions.
Transforming the Future of Pancreatic Cancer Care
Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning.
About Human Longevity, Inc.
Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges.
Media Contactmedia@
View original content to download multimedia:
SOURCE Human Longevity, Inc.
